BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11255 related articles for article (PubMed ID: 10928381)

  • 1. PET imaging in oncology.
    Bar-Shalom R; Valdivia AY; Blaufox MD
    Semin Nucl Med; 2000 Jul; 30(3):150-85. PubMed ID: 10928381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical role of positron emission tomography in oncology.
    Bomanji JB; Costa DC; Ell PJ
    Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
    Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
    Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET in oncology: will it replace the other modalities?
    Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
    Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Positron-emission tomography in oncology].
    Zaplatnikov K; Menzel C; Döbert N; Diehl M; Hamscho N; Grünwald F
    Klin Med (Mosk); 2003; 81(12):13-21. PubMed ID: 14971150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical applications of (18)F-FDG in oncology.
    Nabi HA; Zubeldia JM
    J Nucl Med Technol; 2002 Mar; 30(1):3-9; quiz 10-1. PubMed ID: 11948260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG imaging.
    Coleman RE
    Nucl Med Biol; 2000 Oct; 27(7):689-90. PubMed ID: 11091113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose.
    Giorgetti A; Volterrani D; Mariani G
    Radiol Med; 2002 Apr; 103(4):293-318. PubMed ID: 12107381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effective PET scans in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
    Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A proposal for the rational use of the PET in oncology].
    Borrego Dorado I; Vázquez Albertino R
    Rev Esp Med Nucl; 2002 May; 21(3):163-73. PubMed ID: 12206749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of 18F-FDG PET in evaluating cancers of lung.
    Acker MR; Burrell SC
    J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer].
    Demura Y; Mizuno S; Wakabayashi M; Totani Y; Okamura S; Ameshima S; Ishizaki T; Miyamori I; Ito H; Yonekura Y
    Nihon Kokyuki Gakkai Zasshi; 2000 Sep; 38(9):676-81. PubMed ID: 11109804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic value of positron emission tomography (PET) in clinical oncology].
    Czech N; Brenner W; Kampen WU; Henze E
    Dtsch Med Wochenschr; 2000 May; 125(18):565-7. PubMed ID: 10835983
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cost-effective PET investigations in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
    Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical usefulness of FDG-PET in oncology].
    Sasaki M
    Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
    Graeber GM; Gupta NC; Murray GF
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
    Reske SN; Kotzerke J
    Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 563.